Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities

Lancet. 1998 Sep 26;352(9133):1031-2. doi: 10.1016/S0140-6736(98)00022-1.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anticholesteremic Agents / therapeutic use
  • Atorvastatin
  • Drug Therapy, Combination
  • Gemfibrozil / therapeutic use*
  • Heptanoic Acids / therapeutic use*
  • Humans
  • Hyperlipoproteinemias / chemically induced*
  • Hyperlipoproteinemias / drug therapy*
  • Hypolipidemic Agents / therapeutic use*
  • Protease Inhibitors / adverse effects*
  • Pyrroles / therapeutic use*
  • Ritonavir / adverse effects
  • Saquinavir / adverse effects

Substances

  • Anticholesteremic Agents
  • Heptanoic Acids
  • Hypolipidemic Agents
  • Protease Inhibitors
  • Pyrroles
  • Atorvastatin
  • Saquinavir
  • Ritonavir
  • Gemfibrozil